Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Recruiting · NCT05517811
Conditions: Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma, Control, Pancreas Cancer, Biliary Cancer
At a glance
- Research payments reported, 2025
- $34,200
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- University of Colorado, Denver (with Haemonetics Corporation)
- Tested
- TEG indices (diagnostic_test)
- Dates
- Started 2022-06-26; completion 2028-07-31
- Results posted
- Not yet
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
From ClinicalTrials.gov, last updated 2026-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Haemonetics Corporation reported $34,200 in research payments for this study in 2025 (3 payments).
Products named: Teg6s Hemostasis System, Teg5000 Hemostasis Analyzer
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Colorado Denver $34,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.